Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of ozanimod in secondary progressive multiple sclerosis (SPMS)

Next Previous
Trial Profile

A phase III trial of ozanimod in secondary progressive multiple sclerosis (SPMS)

Planning
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Jan 2018 New trial record
    • 08 Jan 2018 According to a Celgene Corporation media release, the company expects to initiate this trial in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top